设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2021 年第 6 期 第 16 卷

冠心病患者行甲状腺手术围术期使用低分子肝素桥接的安全性分析

Safety of low molecular weight heparin bridging during perioperative period of thyroid surgery in patients with coronary atherosclerotic heart disease

作者:饶远生王建宏刘海鹰闫晓娟杨帆

英文作者:Rao Yuansheng, Wang Jianhong, Liu Haiying, Yan Xiaojuan, Yang Fan

单位:首都医科大学附属北京安贞医院耳鼻咽喉头颈外科100029

英文单位:Department of Otolaryngology-Head and Neck Surgery Beijing Anzhen Hospital Capital Medical University Beijing 100029 China

关键词:冠心病(冠状动脉粥样硬化性心脏病);甲状腺手术;低分子肝素;围术期

英文关键词:Coronaryatheroscleroticheartdisease;Thyroidsurgery;Lowmolecularweightheparin;Perioperativeperiod

  • 摘要:
  • 目的 探讨冠心病(冠状动脉粥样硬化性心脏病)患者行甲状腺手术围术期使用低分子肝素桥接的安全性。方法 选取20158月至20196月于首都医科大学附属北京安贞医院行甲状腺手术的66例冠心病患者作为观察组,另选取66例同期于本院接受相同术式但无冠心病、未接受抗血小板治疗的患者作为对照组,收集2组患者的临床资料进行回顾性分析。观察组围术期予低分子肝素桥接抗凝,对照组术前不予抗凝治疗。比较2组一般资料及术中、术后情况,记录患者围术期严重并发症及死亡情况。结果 观察组年龄、男性比例均高于对照组,差异均有统计学意义(均P0.05)。2组手术时间、术中出血量、术后引流量、引流管留置时间、术后住院时间比较[(151±50min比(146±54min、(48±30ml比(46±34ml、(95±40ml比(90±51ml、(4.1±2.4d比(4.2±3.1d、(7±3d比(7±3d],差异均无统计学意义(均P0.05)。观察组总住院时间长于对照组[(16±3d比(8±5d],差异有统计学意义(t=2.843P0.001)2组患者均顺利完成手术,围术期未出现严重并发症及死亡。结论 需抗血小板治疗的冠心病患者行甲状腺手术围术期使用低分子肝素桥接具有一定安全性,不增加出血风险。

  • Objective To investigate the safety of low molecular weight heparin bridging during perioperative period of thyroid surgery in patients with coronary atherosclerotic heart disease. Methods From August 2015 to June 2019, 66 patients with coronary atherosclerotic heart disease undergoing thyroid surgery in Beijing Anzhen Hospital, Capital Medical University were selected as the observation group. At the same period, 66 patients who had no coronary atherosclerotic heart disease and no antiplatelet therapy undergoing the same types of thyroid surgery in the hospital were selected as the control group. The Clinical data of patients were retrospectively analyzed. The observation group was given low molecular weight heparin bridging anticoagulant therapy during perioperative period, and the control group was not given anticoagulant therapy before operation. The general data, intraoperative and postoperative conditions were compared between the two groups. The serious complications and death during perioperative period were recorded. Results The age and male rate of the observation group were higher than those of the control group(both P<0.05). There were no statistically significant differences in the operation time, intraoperative blood loss, postoperative drainage volume, drainage tube indwelling time, and postoperative length of stay[(151±50min vs 146±54min,48±30ml vs 46±34ml,95±40ml vs 90±51ml,4.1±2.4d vs 4.2±3.1d,7±3d vs 7±3d(all P>0.05). The total length of stay of the observation group was longer than that of the control group[(16±3d vs 8±5d(t=2.843, P0.001). The operation was completed successfully in both groups, and there were no serious complication and death during perioperative period. Conclusion Low molecular weight heparin bridging has certain safety during the perioperative period of thyroid surgery in patients with coronary atherosclerotic heart disease requiring antiplatelet therapy without increasing the risk of bleeding.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭